EP3717452A1 - Procédé de préparation de dérivés d'amphétamine acylés - Google Patents

Procédé de préparation de dérivés d'amphétamine acylés

Info

Publication number
EP3717452A1
EP3717452A1 EP18883053.3A EP18883053A EP3717452A1 EP 3717452 A1 EP3717452 A1 EP 3717452A1 EP 18883053 A EP18883053 A EP 18883053A EP 3717452 A1 EP3717452 A1 EP 3717452A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
amphetamine
iii
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18883053.3A
Other languages
German (de)
English (en)
Other versions
EP3717452A4 (fr
EP3717452B1 (fr
Inventor
Brian Orr
Kevin ROESCH
Joel MCCLENAGHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Specgx LLC
Original Assignee
Specgx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Specgx LLC filed Critical Specgx LLC
Publication of EP3717452A1 publication Critical patent/EP3717452A1/fr
Publication of EP3717452A4 publication Critical patent/EP3717452A4/fr
Application granted granted Critical
Publication of EP3717452B1 publication Critical patent/EP3717452B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present disclosure generally relates to processes for preparing acetylated amphetamine derivatives and, in particular, processes for preparing L-lysine- D-amphetamine dimesylate.
  • L-lysine-D-amphetamine dimesylate also called lisdexamphetamine dimesylate
  • ADHD attention deficit hyperactivity disorder
  • ADD attention deficit disorder
  • BED moderate to severe binge eating disorder
  • CNS central nervous system
  • the D-amphetamine is liberated from lisdexamphetamine enzymatically following contact with red blood cells.
  • the conversion is rate-limited by the enzyme, which prevents high blood concentrations of D-amphetamine and reduces the abuse potential of lisdexamphetamine at clinical doses.
  • One aspect of the present disclosure encompasses a one-pot process for preparing a compound of Formula (IV), which is an acylated amphetamine derivative.
  • the process comprises (a) forming a reaction mixture comprising a solvent and a compound of Formula (I), the solvent being an alkyl tetrahydrofuran; (b) adding a compound of Formula (II) to the reaction mixture, thereby forming an intermediate compound of Formula (III); (c) phase extracting the reaction mixture after step (b) with one or more aqueous solutions to remove the compounds of Formulas (I) and (II) and reaction by-products, thereby forming a purified mixture comprising the intermediate compound of Formula (III); and (d) contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV).
  • the compounds of Formulas (I), (II), (III), and (IV) having the following structures:
  • R is hydrocarbyl or substituted hydrocarbyl
  • LG is a leaving group
  • PG is a protecting group
  • A is an anion
  • Another aspect of the present disclosure provides a one-pot process for preparing L-lysine-D-amphetamine dimesylate.
  • the process comprises (a) converting a D-amphetamine salt to D-amphetamine; (b) adding D-amphetamine to a reaction mixture comprising 2-methyl tetrahydrofuran and L/,/V -di-Boc-L-lysine hydroxysuccinimide ester to form an intermediate compound, the intermediate compound being L/,/V -di-Boc-L-lysine-D-amphetamine; (c) phase extracting the reaction mixture after step (b) with one or more aqueous solutions to remove starting reactants and reaction by-products, thereby forming a purified mixture comprising the
  • the present disclosure provides a simplified one-pot process to prepare crude L-lysine-D-amphetamine dimesylate (lisdexamphetamine dimesylate) from D-amphetamine salts.
  • the protected intermediate formed during the synthesis process is purified by a series of extractions (thus, eliminating the need for expensive, industrial chromatography and isolation of a problematic intermediate), dried by azeotropic distillation. No isolation is carried out until a crude lisdexamphetamine dimesylate is obtained.
  • the crude lisdexamphetamine dimesylate is further purified by recrystallization, which includes a polishing filtration to remove any insoluble material. Cooling and isolation leads to very pure material.
  • the process described herein has industrial applicability, with further improvements to yield (e.g., minimal isolations) and safety (e.g., elimination of toxic solvents such as 1 ,4-dioxane).
  • One aspect of the present disclosure provides a one-pot process for preparing an acylated amphetamine derivative having Formula (IV).
  • the process comprises (a) forming a reaction mixture comprising a solvent and a compound of Formula (I), the solvent being an alkyl tetrahydrofuran; (b) adding a compound of Formula (II) to the reaction mixture, thereby forming an intermediate compound of Formula (III); (c) phase extracting the reaction mixture after step (b) with one or more aqueous solutions to remove the compounds of Formulas (I) and (II) and reaction by- products, thereby forming a purified mixture comprising the intermediate compound of Formula (III); and (d) contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV), as shown in the reaction scheme below.
  • R is hydrocarbyl or substituted hydrocarbyl; LG is a leaving group;
  • PG is a protecting group; and A is an anion.
  • the first step of the process comprises forming a reaction mixture comprising a compound of Formula (I) and a solvent.
  • the compound of Formula (I) comprises a carbonyl group, a leaving group (LG), an R group, and an amino group.
  • the amino group is protected with a protecting group (PG).
  • suitable amino protecting groups include tert- butyloxycarbonyl (Boc), triphenylmethyl (trityl), dimethyl- 3, 5-dimetheoxybenzyloxycarbonyl (Ddz), 2-(4-biphenyl)isopropoxycarbonyl (Bpoc), 2- nitropheylsulfenyl (Nps), 2-chlorobenzyloxycarbonyl (Cl-Z), or 4-methyltrityl (Mtt).
  • the protecting group may be tert- butyloxycarbonyl.
  • R in the compound of Formula (I) may be alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkylamino, substitute alkyamino, alkylhydroxy, substituted alkylhydroxy, alkylthio, substituted alkylthio, alkylaryl, or substituted alkyl aryl.
  • R may be an amino acid side chain.
  • R may be -(CH 2 ) 4 -NH 2 , -(CH 2 ) 3 -NH-C(NH)-NH 2 , -(CH 2 ) 4 -NH-C(NH)-NH 2 - CH 2 -C(0)-NH 2 , -(CH 2 ) 2 -C(0)-NH 2 , -CH 2 -SH, -CH 2 -OH, CH(OH)-CH 3 ,-CH 2 -Ph-OH, - CH2-C(0)-OH, or -(CH 2 ) 2 -C(0)-0H.
  • R may be -(CH 2 ) 4 - NH 2.
  • R is an amino acid side chain
  • the terminal group of the side chain may be protected with a protecting group.
  • suitable amino protecting groups are listed above.
  • suitable hydroxy protecting groups include benzoyl, b-methyoxyethoxym ethyl ether (MEM),
  • MOM methoxymethyl ether
  • PMB p-methoxybenzyl ether
  • the compound of Formula (I) also comprises a leaving group that facilitates amide coupling of the compounds of Formulas (I) and (II).
  • the leaving group may be /V-hydroxysuccinimidyl.
  • the leaving group may be halo, e.g., chloro, fluoro, or bromo.
  • the compound of Formula (I) is a compound of Formula (la):
  • the solvent is a solvent having limited miscibility in water.
  • Suitable solvents include alkyl tetrahydrofurans, benzene, n-butanol, butyl acetate, cyclohexane, 1 ,2-dichloroethane, dichloromethane, ethyl acetate, di-ethyl ether, heptane, hexane, methyl-t-butyl ether, methyl ethyl ketone, pentane, di-iso-propyl ether, toluene, and xylene.
  • the solvent may be an alkyl tetrahydrofuran such as 2-methyl tetrahydrofuran or 3-ethyl tetrahydrofuran.
  • the solvent may be 2-methyl tetrahydrofuran.
  • the amount of solvent added to the reaction mixture can and will vary.
  • the weight ratio of the solvent to the compound of Formula (I) may range from about 2:1 to about 50:1.
  • the weight ratio of the solvent to the compound of Formula (I) may range from about 3:1 to about 20:1 , from about 4: 1 to about 20: 1 , from about 5: 1 to about 15:1 , or from about 6: 1 to about 10:1.
  • Step (b) of the process comprises adding a compound of Formula (II) to the reaction mixture.
  • the compound of Formula (II) a free base of an
  • the compound of Formula (II) is D- amphetamine, which is a compound of Formula (I la): (lla).
  • the compound of Formula (II) may be prepared from an amphetamine salt.
  • suitable amphetamine salts include amphetamine bitartrate, amphetamine sulfate, amphetamine aspartate, amphetamine saccharate, amphetamine hydrochloride, and amphetamine phosphate.
  • the amphetamine salt may be amphetamine bitartrate.
  • the amphetamine salt may be converted to the free base by contact with a base, followed by extraction with the solvent used in the process.
  • Suitable bases include, without limit, hydroxides of alkali metals and alkaline earth metals such as, e.g., sodium hydroxide or potassium hydroxide.
  • the amphetamine salt may be contacted with a hydroxide, followed by several extractions with 2-methyl
  • the 2-methyl tetrahydrofuran phases (comprising the compound of Formula (II)) may be combined and added to the reaction mixture formed in step (a).
  • the amount of the compound of Formula (II) added to the reaction mixture is about equimolar to the amount of Formula (I) present in the reaction mixture.
  • the molar ratio of the compound of Formula (II) to the compound of Formula (I) may range from about 0.8: 1.0 to about 1.2: 1.0, from about 0.9: 1.0 to about 1.1 : 1.0, or from about 0.95:1.00 to about 1.05:1.00.
  • reaction between the compounds of Formula (I) and Formula (II) to form the intermediate compound of Formula (II) proceeds readily at ambient or room temperature. Importantly, the reaction proceeds without the addition of an organic base or an inorganic base.
  • the reaction mixture may be stirred and maintained at ambient or room temperature for at least about 45 minutes, at least about 2 hours, at least about 6 hours, at least 12 hours, at least about 16 hours, or at least about 24 hours.
  • Step (c) of the process comprises extracting the final reaction mixture with one or more aqueous solutions to remove the compounds of Formulas (I) and (II), remove reaction by-products ( e.g ., the leaving group), and organic or inorganic salts, thereby forming a purified mixture comprising the intermediate compound of Formula (III).
  • the intermediate compound of Formula (III) is not isolated from the final reaction mixture after step (b) or the purified mixture following the phase extractions of step (c).
  • the phase extractions comprise sequential contact with a water solution, an acid solution having a pH of less than about 3, an alkaline solution having a pH of greater than about 12, and one or more additional water solutions. After each extraction the aqueous phase is removed and discarded. In general, the phase extractions are conducted at ambient or room temperature.
  • the final purified mixture comprising the alkyl tetrahydrofuran solvent and the intermediate compound of Formula (III) may be azeotropically dried at reflux until the water content of the mixture is less than about 2%, or less than about 1 % by weight (Karl Fischer).
  • the final mixture may be diluted with the same solvent used in step (a).
  • the final mixture may be diluted with the solvent until the concentration of the intermediate compound of Formula (III) ranges from about 8% to about 12% by weight.
  • the final mixture may be diluted with 2- methyl tetrahydrofuran until the concentration of the intermediate compound of Formula (III) is about 10% by weight.
  • Step (d) of the process comprises contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV).
  • Contact with the acid removes the protecting group(s) from the intermediate compound of Formula (III) and forms an acid salt of the compound.
  • suitable acids include methanesulfonic acid, hydrochloric acid, oxalic acid. In specific embodiments, the acid may be methanesulfonic acid.
  • the amount of acid added to the purified mixture comprising the intermediate compound of Formula (III) can and will vary. In general, the molar ratio of the acid to the intermediate compound of Formula (III) may range from about 1 :1 to about 10:1. In some embodiments, the molar ratio of the acid to the intermediate compound of Formula (III) may range from about 2:1 to about 6:1 , or from about 3:1 to about 4:1.
  • Contact with the acid is generally conducted at a temperature ranging from about 40 °C to about 70 °C.
  • the temperature may range from about 40 °C to about 50 °C, from about 50 °C to about 60 °C, or from about 60 °C to about 70 °C.
  • contact with the acid may be conducted at about 50 °C to about 60 °C.
  • the duration of contact with acid at the elevated temperature may proceed for at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 10 hours, or at least about 12 hours.
  • the mixture may than be cooled to ambient or room temperature.
  • the compound of Formula (IV) may be isolated from the solvent/acid mixture by filtration, centrifugation, or other suitable means.
  • the compound of Formula (IV) may be isolated by filtration.
  • the filtration may be accomplished using a Biichner funnel, a filter funnel, or other filter aid.
  • the filtration may be gravity filtration or vacuum filtration.
  • the filtered product may be washed with the solvent used in the process.
  • the final product may be dried at a temperature ranging from about 50 °C to about 70 °C for about 0.5 to about 2 hours in a vacuum oven or a drying oven.
  • the process further comprises recrystallizing the compound of Formula (IV).
  • the isolated compound of Formula (IV) is mixed with a suitable solvent to form a saturated solution.
  • suitable solvents include isopropanol, benzene, butanol, ethanol, ethyl acetate, heptane, methanol, methyl-t-butyl ether, octane, tetrahydrofuran, toluene, combinations thereof, and mixtures of any of the forgoing and water.
  • the solvent may be a mixture of isopropanol and water. In other embodiments, the solvent may be (100%) ethanol.
  • the temperature of the saturated solution may be increased to about 70 °C to enable a polishing filtration to remove insolubles and then cooled to about 4 °C over a period of time.
  • the crystallized compound of Formula (IV) may be isolated by filtration.
  • the filtered compound may washed with the solvent used during the recrystallization process.
  • the polished crystallized compound of Formula (IV) may be dried at a temperature ranging from about 50 °C to about 70 °C in a vacuum oven or a drying oven. The drying may proceed for at least 6 hours, at least 12 hours, at least 18 hours, or at least 24 hours.
  • the yield of the compound of Formula (IV) prepared by the process disclosed herein may be at least about 80%, at least about 85%, at least about 90%, or at least about 95% by weight.
  • the compounds of Formulas (I), (II), (III), and (IV) are compounds of Formulas (la), (I la), (Ilia), and (IV), as shown in the reaction scheme below.
  • Another aspect of the present disclosure encompasses a one-pot process for preparing L-lysine-D-amphetamine dimesylate (i.e., the compound of
  • the process comprises (a) converting a D-amphetamine salt to D- amphetamine; (b) adding D-amphetamine to a reaction mixture comprising 2-methyl tetrahydrofuran (i.e., 2-MeTHF) and L/,L/’-di-Boc-L-lysine hydroxysuccinimide ester (i.e., a protected lysine) to form an intermediate compound, the intermediate compound being L/,/V -di-Boc-L-lysine-D-amphetamine; (c) phase extracting the reaction mixture after step (b) with one or more aqueous solutions to remove starting reactants and reaction by-products, thereby forming a purified mixture comprising the intermediate compound; and (d) contacting the purified mixture comprising the intermediate compound with methanesulfonic acid to form L-lysine-D-amphetamine dimesylate.
  • 2-MeTHF 2-methyl tetrahydrofuran
  • Step (a) comprises contacting the D-amphetamine salt with an alkali metal or alkaline earth metal hydroxide, followed by one or more extractions with 2- methyl tetrahydrofuran.
  • the reaction mixture of step (b) is formed by mixing the protected lysine with 2-MeTFIF.
  • the weight ratio of 2-MeTFIF to the protected lysine may range from about 6:1 to about 10:1 , or about 7:1.
  • Step (b) comprises adding an approximately equimolar amount of D-amphetamine to the protected lysine.
  • Step (b) is allowed to proceed at ambient or room temperature, during which the intermediate compound is formed.
  • the intermediate compound is not isolated. Rather the final reaction mixture comprising the intermediate compound is purified via a series of phase extractions during step (c).
  • the extractions comprise sequential contact with a water solution (which removes the hydroxysuccinimide residue released from the protected lysine during the coupling reaction), an acid solution having a pH of less than about 3 (which removes the unreacted D-amphetamine and hydroxysuccinimide residues), an alkaline solution having a pH of greater than about 12 (which removes the unreacted protected lysine), and one or more additional water solutions (which remove organic and inorganic salts).
  • aqueous phase is removed and discarded.
  • the final purified mixture comprises the intermediate compound with little or no starting materials or reaction by-products.
  • Step (d) comprises maintaining the temperature at about 50-60 °C while adding about 3-4 equivalents of methanesulfonic acid. The temperature is maintained at about 50-60 °C for at least 6-8 hours to ensure complete deprotection of the intermediate compound and formation of L-lysine-D-amphetamine dimesylate.
  • the crystallization step removes undesirable diastereomers, and provides highly pure L-lysine-D-amphetamine dimesylate.
  • D-Amphetamine bitartrate (20.00 g, 0.0701 mol) was suspended in water (40.00 g). To this was added 50 wt. % sodium hydroxide ( ⁇ 7.25 ml_) and 2- MeTHF (30 ml_) to adjust aqueous phase to a pH >13. The actual pH obtained of the aqueous phase was 13.59 at 34.9 °C. The organic phase was separated and the aqueous phase was further extracted (separatory funnel) with 2-MeTHF (90 ml_). The organic phases were combined and used directly in the next example, no drying was required.
  • the 2-MeTHF phase was further successively washed with 2 ml_ of concentrated hydrochloric acid in water (46 ml_) (the pH of aqueous extract was ⁇ 3.00); 2 ml_ of 50 wt. % sodium hydroxide (the pH of extract was > 12.00); and water (46 ml_) three times to remove salts.
  • the 2-MeTHF phase remaining in the flask was set-up for azeotropic distillation using a Dean & Stark apparatus to remove water at a jacket temperature of 80-85 °C for 16 hours in this case. This removed 7.0 mL of water, the 2-MeTHF remaining typically had ⁇ 1.00 wt. % of water remaining.
  • the reaction was then cooled to 50-60 °C and diluted with 2-MeTHF (165 mL), such that the concentration of Di-/V-Boc-L-lysine-D-amphetamine was at 10 wt. % / v based upon 100% yield of lisdexamphetamine dimesylate (i.e., 32.50 g in this example).
  • Methanesulfonic acid (20.21 g, 0.2103 mol) was added such that the temperature was maintained between 50-60 °C; the reaction mixture was then held at this temperature to ensure complete deprotection for a least 6-8 hours.
  • reaction mixture was then cooled to room temperature and filtered on a Buchner funnel and washed with 2-MeTHF (50 ml_). After air drying for 1 hour, the crude (30.69 g) was dried in a vacuum oven at 60 °C, 22”Hg. This afforded crude lisdexamphetamine dimesylate as a white solid (30.25 g. 94.70 %‘as-is’, typically assaying at > 95 wt. %, with the excess being excess methanesulfonic acid and solvents, etc.).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des procédés de préparation de dérivés d'amphétamine acétylés et, en particulier, des procédés de préparation de dimésylate de L-lysine-D-amphétamine à partir de sels de D-amphétamine.
EP18883053.3A 2017-11-30 2018-11-27 Procédé de préparation de dérivés d'amphétamine acylés Active EP3717452B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592503P 2017-11-30 2017-11-30
PCT/US2018/062624 WO2019108542A1 (fr) 2017-11-30 2018-11-27 Procédé de préparation de dérivés d'amphétamine acylés

Publications (3)

Publication Number Publication Date
EP3717452A1 true EP3717452A1 (fr) 2020-10-07
EP3717452A4 EP3717452A4 (fr) 2021-08-25
EP3717452B1 EP3717452B1 (fr) 2024-06-05

Family

ID=66634896

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18883053.3A Active EP3717452B1 (fr) 2017-11-30 2018-11-27 Procédé de préparation de dérivés d'amphétamine acylés

Country Status (9)

Country Link
US (1) US10927068B2 (fr)
EP (1) EP3717452B1 (fr)
JP (1) JP7263350B2 (fr)
AU (1) AU2018374838B2 (fr)
CA (1) CA3081841A1 (fr)
DK (1) DK3717452T3 (fr)
MX (1) MX2020005151A (fr)
PT (1) PT3717452T (fr)
WO (1) WO2019108542A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089666A1 (fr) 2022-10-28 2024-05-02 Macfarlan Smith Limited Procédé de préparation de lisdexamfétamine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
WO2010042120A1 (fr) 2008-10-09 2010-04-15 Archimica, Inc. Procédé pour la synthèse de dérivés d’amphétamine
WO2010148305A1 (fr) 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Procédés et compositions pour la préparation de conjugués d'amphétamine et de sels de ceux-ci
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
WO2013011526A1 (fr) 2011-07-20 2013-01-24 Ind-Swift Laboratories Limited Procédé de préparation de la lisdexamphétamine et de ses sels
US20140171510A1 (en) 2011-07-29 2014-06-19 Shire Llc Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
US10544434B2 (en) * 2015-06-29 2020-01-28 Noramco, Inc. Process for the preparation of lisdexamfetamine and related derivatives

Also Published As

Publication number Publication date
CA3081841A1 (fr) 2019-06-06
US20190161435A1 (en) 2019-05-30
EP3717452A4 (fr) 2021-08-25
AU2018374838B2 (en) 2023-10-05
AU2018374838A1 (en) 2020-05-28
PT3717452T (pt) 2024-08-28
MX2020005151A (es) 2020-08-20
EP3717452B1 (fr) 2024-06-05
BR112020010650A2 (pt) 2020-11-17
WO2019108542A1 (fr) 2019-06-06
JP7263350B2 (ja) 2023-04-24
DK3717452T3 (da) 2024-08-19
US10927068B2 (en) 2021-02-23
JP2021504324A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
AU2018374838B2 (en) Process for preparing acylated amphetamine derivatives
KR100346672B1 (ko) 3-o-치환 아스코르브산의 제조방법
CA2368815A1 (fr) Nouvelle synthese et cristallisation de composes contenant de la piperazine
CZ290128B6 (cs) Způsob přípravy 1,4,7,10-tetraazacyklododekanu a jeho derivátů
US6576764B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
EP2139899B1 (fr) Formes cristallines de chlorhydrate de topotécan et leurs procédés de préparation
US20190284126A1 (en) Method for preparation of (s)-n1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride
PL188634B1 (pl) Sposób wytwarzania potasowej soli kwasu klawulanowego
WO2012019862A1 (fr) Procédé pour fabriquer du linézolid
JP2022535112A (ja) ４－フェニル－５－アルコキシカルボニル－２－チアゾール－２－イル－１，４－ジヒドロピリミジン－６－イル］メチル］－３－オキソ－５，６，８，８ａ－テトラヒドロ－１Ｈ－イミダゾ［１，５－ａ］ピラジン－２－イル］－カルボン酸を調製するための代替方法
EP3105214A1 (fr) Nouveau procédé de production de chlorhydrate de nébivolol de haute pureté
CN111808040B (zh) 多构型2-氧代噁唑烷-4-羧酸类化合物的合成方法
BR112020010650B1 (pt) Processo para preparar derivados de anfetamina acilada
CN101654426A (zh) 制备伊洛马司他的方法
EP3031800B1 (fr) Procédé pour la préparation de miglustat de haute pureté
US20040176591A1 (en) Novel synthesis and crystallization of peperazine ring-containing compounds
US2806859A (en) L-glutamine synthesis
FR2790472A1 (fr) Derives de cyclobutene-3, 4-dione, leur preparation et leur application en therapeutique
SU382622A1 (ru) Способ получения \-а1у1ино-или-ы-оксизал^ещенных гетероциклических соединений
CN116217553A (zh) 一种三嗪酮类化合物及其制备方法和应用
AU2005201117A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
EP2690100A1 (fr) Proécdé pour la préparation de Linezolid

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210726

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 231/02 20060101AFI20210720BHEP

Ipc: C07C 237/06 20060101ALI20210720BHEP

Ipc: C07C 269/04 20060101ALI20210720BHEP

Ipc: C07C 231/12 20060101ALI20210720BHEP

Ipc: C07C 231/24 20060101ALI20210720BHEP

Ipc: C07C 269/06 20060101ALI20210720BHEP

Ipc: C07C 269/08 20060101ALI20210720BHEP

Ipc: C07C 271/22 20060101ALI20210720BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 271/22 20060101ALI20231117BHEP

Ipc: C07C 269/08 20060101ALI20231117BHEP

Ipc: C07C 269/06 20060101ALI20231117BHEP

Ipc: C07C 231/24 20060101ALI20231117BHEP

Ipc: C07C 231/12 20060101ALI20231117BHEP

Ipc: C07C 269/04 20060101ALI20231117BHEP

Ipc: C07C 237/06 20060101ALI20231117BHEP

Ipc: C07C 231/02 20060101AFI20231117BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240104

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240417

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018070400

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20240813

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3717452

Country of ref document: PT

Date of ref document: 20240828

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20240823